Vicore Pharma Holding Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
VICO
- Investments
-
5
- Share Price
-
$1.07
- (As of Friday Closing)
Vicore Pharma Holding General Information
Description
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Contact Information
Website
www.vicorepharma.comCorporate Office
- Kornhamnstorg 53
- 111 27 Stockholm
- Sweden
Corporate Office
- Kornhamnstorg 53
- 111 27 Stockholm
- Sweden
Vicore Pharma Holding Timeline
Vicore Pharma Holding Stock Performance
As of 13-Nov-2026, Vicore Pharma Holding’s stock price is $1.07. Its current market cap is $301M with 282M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.07 | $1.10 | $0.86 - $1.89 | $301M | 282M | 1.12M | -$0.20 |
Vicore Pharma Holding Financials Summary
As of 30-Sep-2026, Vicore Pharma Holding has a trailing 12-month revenue of $407K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 179,206 | 255,327 | 145,532 | 103,335 |
| Revenue | 407 | 389 | 10,339 | 0 |
| EBITDA | (58,790) | (51,025) | (17,750) | (29,959) |
| Net Income | (55,818) | (48,599) | (15,945) | (29,254) |
| Total Assets | 82,008 | 132,433 | 108,359 | 49,814 |
| Total Debt | 0 | 0 | 0 | 0 |
Vicore Pharma Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vicore Pharma Holding Comparisons
Industry
Financing
Details
Vicore Pharma Holding Competitors (7)
One of Vicore Pharma Holding’s 7 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Savara | Formerly VC-backed | Yardley, PA | ||||
| Avalyn Pharma | Formerly VC-backed | Boston, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
Vicore Pharma Holding Patents
Vicore Pharma Holding Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019263701-A1 | New treatment of interstitial lung diseases | Inactive | 03-May-2018 | ||
| CA-3099008-A1 | New treatment of interstitial lung diseases | Inactive | 03-May-2018 | ||
| EP-3787599-A1 | New treatment of interstitial lung diseases | Inactive | 03-May-2018 | ||
| US-20210236425-A1 | New treatment of interstitial lung diseases | Inactive | 03-May-2018 | ||
| WO-2019211624-A1 | New treatment of interstitial lung diseases | Inactive | 03-May-2018 | A61K9/143 |
Vicore Pharma Holding Signals
Vicore Pharma Holding Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vicore Pharma Holding Investments & Acquisitions (5)
Vicore Pharma Holding’s most recent deal was a Corporate Asset Purchase with HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) for . The deal was made on 02-Nov-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) | 02-Nov-2020 | Corporate Asset Purchase | Buildings and Property | ||
| INIM Pharma | 20-Aug-2018 | Merger/Acquisition | Drug Discovery | ||
| I-Tech (Molndal) | 08-Feb-2018 | Later Stage VC | Industrial Chemicals | ||
| I-Tech (Molndal) | 01-Mar-2011 | Later Stage VC | Industrial Chemicals | ||
| I-Tech (Molndal) | 01-Jan-2000 | Early Stage VC | Industrial Chemicals |
Vicore Pharma Holding ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.19 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vicore Pharma Holding Exits (3)
Vicore Pharma Holding’s most recent exit was on 08-Feb-2018 from I-Tech (Molndal). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| I-Tech (Molndal) | 08-Feb-2018 | Completed |
|
||
| I-Tech (Molndal) | 01-Mar-2011 | Completed |
|
||
| I-Tech (Molndal) | 01-Jan-2000 | Early Stage VC | Completed |
|
Vicore Pharma Holding Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| INIM Pharma | Sweden | 2018 |
Vicore Pharma Holding FAQs
-
When was Vicore Pharma Holding founded?
Vicore Pharma Holding was founded in 2000.
-
Where is Vicore Pharma Holding headquartered?
Vicore Pharma Holding is headquartered in Stockholm, Sweden.
-
What is the size of Vicore Pharma Holding?
Vicore Pharma Holding has 40 total employees.
-
What industry is Vicore Pharma Holding in?
Vicore Pharma Holding’s primary industry is Drug Discovery.
-
Is Vicore Pharma Holding a private or public company?
Vicore Pharma Holding is a Public company.
-
What is Vicore Pharma Holding’s stock symbol?
The ticker symbol for Vicore Pharma Holding is VICO.
-
What is the current stock price of Vicore Pharma Holding?
As of 13-Nov-2026 the stock price of Vicore Pharma Holding is $1.07.
-
What is the current market cap of Vicore Pharma Holding?
The current market capitalization of Vicore Pharma Holding is $301M.
-
What is Vicore Pharma Holding’s current revenue?
The trailing twelve month revenue for Vicore Pharma Holding is $407K.
-
Who are Vicore Pharma Holding’s competitors?
Savara, Avalyn Pharma, Gilead, Biogen, and Amgen are some of the 7 competitors of Vicore Pharma Holding.
-
What is Vicore Pharma Holding’s annual earnings per share (EPS)?
Vicore Pharma Holding’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process